BR0108997A - Terapia imune adjuvante para hiv - Google Patents

Terapia imune adjuvante para hiv

Info

Publication number
BR0108997A
BR0108997A BR0108997-8A BR0108997A BR0108997A BR 0108997 A BR0108997 A BR 0108997A BR 0108997 A BR0108997 A BR 0108997A BR 0108997 A BR0108997 A BR 0108997A
Authority
BR
Brazil
Prior art keywords
hiv
interferon alfa
immune therapy
pegylated interferon
adjuvant immune
Prior art date
Application number
BR0108997-8A
Other languages
English (en)
Inventor
Mark A Laughlin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR0108997A publication Critical patent/BR0108997A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"TERAPIA IMUNE ADJUVANTE PARA HIV". é descrita a utilização de interrferon alfa, por exemplo, interrferon alfa-2a ou 2b peguilado para a preparação de drogas para a promoção de uma resposta imune HIV-1 específica, por exemplo, a promoção de células-T, HIV-1 específicas, em pacientes adultos e pediátricos tendo infecções por HIV-1 assim como pacientes co-infectados por HIV-1 e HCV, compreendendo uma quantidade terapeuticamente eficaz de interrferon alfa peguilado, por exemplo, interrferon alfa-2b peguilado.
BR0108997-8A 2000-03-09 2001-03-08 Terapia imune adjuvante para hiv BR0108997A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18833800P 2000-03-09 2000-03-09
PCT/US2001/007453 WO2001066132A2 (en) 2000-03-09 2001-03-08 Hiv immune adjuvant therapy

Publications (1)

Publication Number Publication Date
BR0108997A true BR0108997A (pt) 2003-06-03

Family

ID=22692745

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108997-8A BR0108997A (pt) 2000-03-09 2001-03-08 Terapia imune adjuvante para hiv

Country Status (14)

Country Link
US (1) US20020004584A1 (pt)
EP (1) EP1263457A2 (pt)
JP (1) JP2003525907A (pt)
CN (1) CN1416351A (pt)
AU (1) AU2001249120A1 (pt)
BR (1) BR0108997A (pt)
CA (1) CA2402024A1 (pt)
HK (1) HK1047406A1 (pt)
HU (1) HUP0300354A3 (pt)
MX (1) MXPA02008756A (pt)
NO (1) NO20024255D0 (pt)
NZ (1) NZ520055A (pt)
WO (1) WO2001066132A2 (pt)
ZA (1) ZA200205846B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9849372B2 (en) 2012-09-28 2017-12-26 Sony Interactive Entertainment Inc. Method and apparatus for improving efficiency without increasing latency in emulation of a legacy application title
CN1944644B (zh) * 2006-06-20 2011-11-16 浙江大学 HIV-1gp120与人γ干扰素融合蛋白的制备方法
CA3240281A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
US9925468B2 (en) 2012-06-29 2018-03-27 Sony Interactive Entertainment Inc. Suspending state of cloud-based legacy applications
US9694276B2 (en) 2012-06-29 2017-07-04 Sony Interactive Entertainment Inc. Pre-loading translated code in cloud based emulated applications
EP2877598A1 (en) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
US10406429B2 (en) 2012-08-29 2019-09-10 Sony Interactive Entertainment, LLC User-based mini-game generation and distribution
US11013993B2 (en) 2012-09-28 2021-05-25 Sony Interactive Entertainment Inc. Pre-loading translated code in cloud based emulated applications
US9707476B2 (en) 2012-09-28 2017-07-18 Sony Interactive Entertainment Inc. Method for creating a mini-game
PE20151604A1 (es) 2012-11-02 2015-11-04 Pharmacyclics Llc Terapia adyuvante con inhibidores de quinasa de la familia tec
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
MX9307733A (es) * 1992-12-23 1994-06-30 Schering Corp Restauracion de la funcion inmunologica en pacientes asintomaticos de vih-positivo.
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
EP0730470B1 (en) * 1993-11-10 2002-03-27 Enzon, Inc. Improved interferon polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5780220A (en) * 1994-05-19 1998-07-14 Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting HIV replication
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
CO5160259A1 (es) * 1999-03-02 2002-05-30 Schering Corp Interferon alfa pegilado en la terapia contra el hiv
US20020182179A1 (en) * 1999-03-02 2002-12-05 Laughlin Mark A HIV Therapy

Also Published As

Publication number Publication date
JP2003525907A (ja) 2003-09-02
CN1416351A (zh) 2003-05-07
HUP0300354A3 (en) 2005-07-28
ZA200205846B (en) 2003-10-22
EP1263457A2 (en) 2002-12-11
CA2402024A1 (en) 2001-09-13
HK1047406A1 (zh) 2003-02-21
NO20024255L (no) 2002-09-06
NZ520055A (en) 2004-06-25
AU2001249120A1 (en) 2001-09-17
US20020004584A1 (en) 2002-01-10
WO2001066132A3 (en) 2002-01-24
NO20024255D0 (no) 2002-09-06
WO2001066132A2 (en) 2001-09-13
HUP0300354A2 (hu) 2003-06-28
MXPA02008756A (es) 2003-02-24

Similar Documents

Publication Publication Date Title
BR0114636A (pt) Terapia combinada para hcv de interferon-alfa peguilado/ribavirina
HUP0103423A2 (hu) Ribavirint és alfa-interferont tartalmazó kombinált terápia vírusellenes kezelésben nem részesült, krónikus hepatitis C fertőzött paciensek kezelésében
BR0010593A (pt) Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv
PE119199A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica
ES2069582T3 (es) Nucleosidos terapeuticos.
CL2010000828A1 (es) Composicion farmaceutica que comprende un conjugado pegilado de interferon alfa y ribavirina, util en la preparacion de un medicamento para las infecciones de hepatitis c cronica.
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
HK1084862A1 (en) Use of omega interferon in the manufacturing of a medicament for treating viral disease in a warm-blooded animal subject
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
BR0009840A (pt) Terapia de combinação para hcv, contendo ribavirina em associação com antioxidantes
BR0108997A (pt) Terapia imune adjuvante para hiv
BR0316227A (pt) IsÈmeros posicionais de peg ifn alfa 2a
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
BR9913951A (pt) Tratamento de infecção de hepatite b com timosina alfa 1 em combinação com lamivudina e flamciclovir
AR029337A1 (es) Uso de interferon alfa pegilado para la preparacion de un medicamento para la terapia contra el hiv
ES2160927T3 (es) Composiciones farmaceuticas que comprenden interferon alfa humano natural.
BRPI0409711A (pt) tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina
MD2053C2 (ro) Remediu cu acţiune interferonogenă
Sulkowski Hepatitis C virus and HIV co-infection: a sleeping giant wakes
ECSP003462A (es) Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado (caso ino1024k)
ECSP003373A (es) Terapia contra el hiv
IT9082002A0 (it) Siringa monouso per la preparazione e l'iniezione di farmaci a soluzione estemporanea precontenuti nel suo corpo.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008.